A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults (HypoCCS)

• Evaluate long-term benefits of somatropin replacement therapy with regard to cardiovascular risk factors. [ Time Frame: At interim timepoints and at study completion ] [ Designated as safety issue: Yes ]
• Evaluate long-term benefits of somatropin replacement therapy with regard to fracture incidence. [ Time Frame: At interim timepoints and at study completion ] [ Designated as safety issue: Yes ]
• Evaluate long-term benefits of somatropin replacement therapy with regard to quality of life as assessed by a disease-specific module of the Questions of Life Satisfaction (QLS-H). [ Time Frame: At interim timepoints and at study completion ] [ Designated as safety issue: No ]

The Hypopituitary Control and Complications Study "HypoCCS" is a prospective, open label, global, multicentre, observational study on routine clinical care of adults with growth hormone deficiency occurring either isolated or in combination with other pituitary hormone deficiencies. The objective of this observational study is to evaluate long-term safety and health outcomes for adult growth hormone deficient patients with or without somatropin replacement therapy. As an observational study, data are collected only as provided at the discretion of the attending physician. The patients enrolled meet the criteria of growth hormone deficiency in adults as per the Humatrope label in the country where their attending physician practices, and this diagnosis is at the discretion of the attending physician. The decision to receive somatropin or remain untreated is made by the patient in consultation with their attending physician.

While treatment of adult growth hormone deficient patients with somatropin has been shown to be safe and effective in clinical trials of 18 months duration, this observational study aims to provide information on health outcome and replacement therapy over longer periods of time for a larger number of patients in the context of the overall disease environment.

Clinics, private practices

• Hypopituitarism
• Pituitary Insufficiency
• Growth Hormone Deficiency, Adult

• Somatropin replacement treatment
  Adult patients with growth hormone deficiency receiving somatropin replacement treatment.
  Intervention: Drug: Somatropin (rDNA origin)
• No treatment
  Adult patients with growth hormone deficiency receiving no somatropin replacement treatment.

Inclusion Criteria:

- Adult growth hormone deficiency as per the local Humatrope label and as judged by the attending physician

Exclusion Criteria:

- As per the local Humatrope label and as judged by the attending physician